Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Dumas, Rémy ^a,b   Richieri, Raphaëlle ^a,b,e   Guedj, Eric ^c,d,e   Auquier, Pascal ^b,f   Lancon, Christophe ^a,b   Boyer, Laurent ^b,f  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c TIMONE HOSPITAL   (France)

^d Aix Marseille University   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Depression; Health related quality of life; Precuneus; Repetitive Transcranial Magnetic Stimulation (rTMS); Single photon emission computed tomography (SPECT)

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CLINICAL ARTICLE; DISEASE ASSOCIATION; DSM-IV; EFFECT SIZE; FUNCTIONAL NEUROIMAGING; HUMAN; MAJOR DEPRESSION; MENTAL HEALTH; NATURALISTIC INQUIRY; PRECUNEUS; QUALITY OF LIFE; SHORT FORM 36; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL INTERACTION; TRANSCRANIAL MAGNETIC STIMULATION; VOXEL BASED MORPHOMETRY;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; FUNCTIONAL NEUROIMAGING; HUMANS; MALE; MIDDLE AGED; PERFUSION IMAGING; QUALITY ASSURANCE, HEALTH CARE; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE; SOCIOECONOMIC FACTORS; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84864240201     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-87     Document Type: Article

References (62)

1. American Psychiatric Association DSM-IV. Diagnostic and Statistical Manual of Mental Disorders 1994, Washington: American Psychiatric Association, 4, American Psychiatric Association.
2. The World Health Report Health Systems: Improving Performance 2000, Geneva: World Health Organization, The World Health Report.
3. George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 1995, 6:1853-1856. 10.1097/00001756-199510020-00008, 8547583.
4. Rumi DO, Gattaz WF, Rigonatti SP, Rosa MA, Fregni F, Rosa MO, Mansur C, Myczkowski ML, Moreno RA, Marcolin MA. Transcranial magnetic stimulation accelerates the antidepressant effect of amitriptyline in severe depression: a double-blind placebo-controlled study. Biol Psychiatry 2005, 57:162-166. 10.1016/j.biopsych.2004.10.029, 15652875.
5. Lefaucheur J-P, André-Obadia N, Poulet E, Devanne H, Haffen E, Londero A, Cretin B, Leroi A-M, Radtchenko A, Saba G, Thai-Van H, Litré C-F, Vercueil L, Bouhassira D, Ayache S-S, Farhat W-H, Zouari H-G, Mylius V, Nicolier M, Garcia-Larrea L. French guidelines on the use of repetitive transcranial magnetic stimulation (rTMS): safety and therapeutic indications. Neurophysiol Clin 2011, 41:221-295. 10.1016/j.neucli.2011.10.062, 22153574.
6. Chen R, Classen J, Gerloff C, Celnik P, Wassermann EM, Hallett M, Cohen LG. Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 1997, 48:1398-1403. 10.1212/WNL.48.5.1398, 9153480.
7. Pascual-Leone A, Valls-Solé J, Wassermann EM, Hallett M. Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain 1994, 117(Pt 4):847-858.
8. Berlim MT, McGirr A, Beaulieu M-M, Turecki G. High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: a prospective 4-week naturalistic trial. J Affect Disord 2011, 130:312-317. 10.1016/j.jad.2010.10.011, 21056475.
9. McLoughlin DM. Review: high frequency repetitive transcranial magnetic stimulation improves symptoms of major depression. Evid Based Ment Health 2009, 12:80-81. 10.1136/ebmh.12.3.80, 19633248.
10. Gross M, Nakamura L, Pascual-Leone A, Fregni F. Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. Acta Psychiatr Scand 2007, 116:165-173. 10.1111/j.1600-0447.2007.01049.x, 17655557.
11. Schutter DJLG. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med 2010, 40:1789-1795. 10.1017/S003329171000005X, 20102670.
12. Slotema CW, Blom JD, Hoek HW, Sommer IEC. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010, 71:873-884. 10.4088/JCP.08m04872gre, 20361902.
13. Eche J, Mondino M, Haesebaert F, Saoud M, Poulet E, Brunelin J. Low- vs high-frequency repetitive transcranial magnetic stimulation as an add-on treatment for refractory depression. Front Psychiatry 2012, 3:13. 3296064, 22408627.
14. Fitzgerald PB, Hoy K, Daskalakis ZJ, Kulkarni J. A randomized trial of the anti-depressant effects of low- and high-frequency transcranial magnetic stimulation in treatment-resistant depression. Depress Anxiety 2009, 26:229-234. 10.1002/da.20454, 19105212.
15. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 2004, 26:13-17. 10.1016/j.genhosppsych.2003.07.004, 14757297.
16. De Fruyt J, Demyttenaere K. Quality of life measurement in antidepressant trials. Is there an added value?. Psychother Psychosom 2009, 78:212-219. 10.1159/000214442, 19401621.
17. Kennedy SH, Eisfeld BS, Cooke RG. Quality of life: an important dimension in assessing the treatment of depression?. J Psychiatry Neurosci 2001, 26(Suppl):S23-28. 2553258, 11590966.
18. Gilbody SM, House AO, Sheldon TA. Psychiatrists in the UK do not use outcomes measures. National survey. Br J Psychiatry 2002, 180:101-103. 10.1192/bjp.180.2.101, 11823316.
19. Greenhalgh J, Long AF, Flynn R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory?. Soc Sci Med 2005, 60:833-843. 10.1016/j.socscimed.2004.06.022, 15571900.
20. Berlim MT, Pargendler J, Brenner J, Fleck MPA. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res 2007, 153:253-259. 10.1016/j.psychres.2006.07.006, 17675247.
21. Demyttenaere K, Andersen HF, Reines EH. Impact of escitalopram treatment on quality of life enjoyment and satisfaction questionnaire scores in major depressive disorder and generalized anxiety disorder. Int Clin Psychopharmacol 2008, 23:276-286. 10.1097/YIC.0b013e328303ac5f, 18703937.
22. Skevington SM, Lotfy M, O'Connell KA. The world health organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004, 13:299-310.
23. Leplège A, Ecosse E, Verdier A, Perneger TV. The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 1998, 51:1013-1023. 10.1016/S0895-4356(98)00093-6, 9817119.
24. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
25. Hadley D, Anderson BS, Borckardt JJ, Arana A, Li X, Nahas Z, George MS. Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. J ECT 2011, 27:18-25. 10.1097/YCT.0b013e3181ce1a8c, 21343710.
26. Theodore WH, Hunter K, Chen R, Vega-Bermudez F, Boroojerdi B, Reeves-Tyer P, Werhahn K, Kelley KR, Cohen L. Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology 2002, 59:560-562. 10.1212/WNL.59.4.560, 12196649.
27. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics 2012, 30:183-195. 10.2165/11594470-000000000-00000, 22263841.
28. Boyer L, Richieri R, Faget C, Padovani R, Vaillant F, Mundler O, Lançon C, Auquier P, Guedj E. Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia. Psychiatry Res 2012, 202:155-160. 10.1016/j.pscychresns.2012.02.006, 22698762.
29. Richieri R, Boyer L, Farisse J, Colavolpe C, Mundler O, Lancon C, Guedj E. Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression. Eur J Nucl Med Mol Imaging 2011, 38:1715-1722. 10.1007/s00259-011-1850-9, 21647787.
30. Richieri R, Boyer L, Lançon C, Guedj E. Predict the outcome of depression after rTMS using neuroimaging: Issue of response or non-response?. Brain Stimul 2012,
31. Faget-Agius C, Boyer L, Padovani R, Richieri R, Mundler O, Lançon C, Guedj E. Schizophrenia with preserved insight is associated with increased perfusion of the precuneus. J Psychiatry Neurosci 2012, 37:110125.
32. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck depression inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996, 67:588-597. 10.1207/s15327752jpa6703_13, 8991972.
33. CNIL Act n°78-17 of 6 January 1978 on Data Processing, Data Files and Individual Liberties (amended by the Act of 6 August 2004 relating to the protection of individuals with regard to the processing of personal data) 2004, France: Journal officiel de la République Française. Assemblée Nationale et Sénat, CNIL.
34. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045. World Medical Association.
35. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113. 10.1016/0028-3932(71)90067-4, 5146491.
36. Thalheimer W, Cook S. How to calculate effect sizes from published research articles: A simplified methodology 2002, August. Retrieved January 2, 2012 from http://work-learning.com/effect_sizes.htm.
37. Huang I-C, Wu AW, Frangakis C. Do the SF-36 and WHOQOL-BREF measure the same constructs? Evidence from the Taiwan population*. Qual Life Res 2006, 15:15-24. 10.1007/s11136-005-8486-9, 16411027.
38. Jamieson J. Dealing with baseline differences: two principles and two dilemmas. Int J Psychophysiol 1999, 31:155-161. 10.1016/S0167-8760(98)00048-8, 9987061.
39. Cavanna AE, Trimble MR. The precuneus: a review of its functional anatomy and behavioural correlates. Brain 2006, 129:564-583. 10.1093/brain/awl004, 16399806.
40. Kito S, Hasegawa T, Koga Y. Neuroanatomical correlates of therapeutic efficacy of low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression. Psychiatry Clin Neurosci 2011, 65:175-182. 10.1111/j.1440-1819.2010.02183.x, 21414091.
41. Lou HC, Luber B, Crupain M, Keenan JP, Nowak M, Kjaer TW, Sackeim HA, Lisanby SH. Parietal cortex and representation of the mental self. Proc Natl Acad Sci USA 2004, 101:6827-6832. 10.1073/pnas.0400049101, 404216, 15096584.
42. Kjaer TW, Nowak M, Lou HC. Reflective self-awareness and conscious states: PET evidence for a common midline parietofrontal core. Neuroimage 2002, 17:1080-1086. 10.1006/nimg.2002.1230, 12377180.
43. Nardo D, Högberg G, Flumeri F, Jacobsson H, Larsson SA, Hällström T, Pagani M. Self-rating scales assessing subjective well-being and distress correlate with rCBF in PTSD-sensitive regions. Psychol Med 2011, 45:2549-2561.
44. Ritsner M, Kurs R, Gibel A, Hirschmann S, Shinkarenko E, Ratner Y. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003, 64:308-315. 10.4088/JCP.v64n0313, 12716273.
45. Ritsner M, Gibel A, Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Qual Life Res 2006, 15:515-526. 10.1007/s11136-005-2808-9, 16547790.
46. Mor N, Winquist J. Self-focused attention and negative affect: a meta-analysis. Psychol Bull 2002, 128:638-662.
47. Lemogne C, Gorwood P, Bergouignan L, Pélissolo A, Lehéricy S, Fossati P. Negative affectivity, self-referential processing and the cortical midline structures. Soc Cogn Affect Neurosci 2011, 6:426-433. 10.1093/scan/nsq049, 3150850, 20519253.
48. Bögels SM, Mansell W. Attention processes in the maintenance and treatment of social phobia: hypervigilance, avoidance and self-focused attention. Clin Psychol Rev 2004, 24:827-856. 10.1016/j.cpr.2004.06.005, 15501558.
49. Delaveau P, Jabourian M, Lemogne C, Guionnet S, Bergouignan L, Fossati P. Brain effects of antidepressants in major depression: a meta-analysis of emotional processing studies. J Affect Disord 2011, 130:66-74. 10.1016/j.jad.2010.09.032, 21030092.
50. Duval C, Desgranges B, Eustache F, Piolino P. Looking at the self under the microscope of cognitive neurosciences: from self-consciousness to consciousness of others. Psychol Neuropsychiatr Vieil 2009, 7:7-19.
51. Saxe R, Moran JM, Scholz J, Gabrieli J. Overlapping and non-overlapping brain regions for theory of mind and self reflection in individual subjects. Soc Cogn Affect Neurosci 2006, 1:229-234. 10.1093/scan/nsl034, 2555418, 18985110.
52. Wolkenstein L, Schönenberg M, Schirm E, Hautzinger M. I can see what you feel, but I can't deal with it: Impaired theory of mind in depression. J Affect Disord 2011, 132:104-111. 10.1016/j.jad.2011.02.010, 21420177.
53. Goldin P, Ramel W, Gross J. Mindfulness meditation training and self-referential processing in social anxiety disorder: behavioral and neural effects. J Cogn Psychotherapy 2009, 23:242-257.
54. Boyer L, Millier A, Perthame E, Aballea S, Auquier P, Toumi M. Quality of life is predictive of relapse in schizophrenia. BMC Psychiatry In press.
55. Parshall MB, Mapel DW, Rice L, Williams A, O'Reilly J. Predictive validity of short-form health survey [36 items] scales for chronic obstructive pulmonary disease exacerbation. Heart Lung 2008, 37:356-365. 10.1016/j.hrtlng.2007.09.007, 18790336.
56. Fitzgerald PB, Hoy K, McQueen S, Maller JJ, Herring S, Segrave R, Bailey M, Been G, Kulkarni J, Daskalakis ZJ. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacology 2009, 34:1255-1262. 10.1038/npp.2008.233, 19145228.
57. Hadj Ammar M, Khammouma S, Nasr M. Depressive disorders and quality of life: a cross sectional study including 360 depressive patients followed at the psychiatry consultation of the Mahdia university hospital. Encephale 2008, 34:256-262. 10.1016/j.encep.2006.11.001, 18558146.
58. Kuehner C, Buerger C. Determinants of subjective quality of life in depressed patients: the role of self-esteem, response styles, and social support. J Affect Disord 2005, 86:205-213. 10.1016/j.jad.2005.01.014, 15935240.
59. Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M, Berman SR, Farabaugh A, Luther JF, Nierenberg AA, Callan JA, Sackeim HA. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry 2006, 67:185-195. 10.4088/JCP.v67n0203, 16566612.
60. Brunoni AR, Lopes M, Kaptchuk TJ, Fregni F. Placebo response of non-pharmacological and pharmacological trials in major depression: a systematic review and meta-analysis. PLoS ONE 2009, 4:e4824. 10.1371/journal.pone.0004824, 2653635, 19293925.
61. Furukawa TA. Assessment of mood: guides for clinicians. J Psychosom Res 2010, 68:581-589. 10.1016/j.jpsychores.2009.05.003, 20488276.
62. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, Watanabe N, Maeda T, Furukawa TA. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005, 135:229-235. 10.1016/j.psychres.2004.03.014, 15996749.